Caribou Biosciences appoints Ran Zheng to board of directors

Caribou Biosciences, Inc.

Board increased from 5 to 6 directors; Zheng appointed Class I director and to Nominating Committee.
Zheng receives $40,000/yr board cash compensation plus $4,000/yr committee cash compensation.
Initial grant of 44,000 non-qualified stock options, vesting over 3 years starting Oct 1, 2022.
Zheng brings 25+ years biotech experience, most recently CEO of Landmark Bio and CTO at Orchard Therapeutics.
Press release issued Sep 29, 2021; option exercise price = closing price on Oct 1, 2021 grant date.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Ran Zheng

Class I Director

CRBU · Caribou Biosciences, Inc.

Effective: 2021-09-24
Filed: September 29, 2021, 7:59 PM ET

On September 24, 2021, the Board of Directors (the “Board”) of Caribou Biosciences, Inc., a Delaware corporation (the “Company”), increased the size of the Board from five to six directors and unanimously agreed to extend an offer to Ran Zheng to serve as a Class I director of the Company, which offer Ms. Zheng accepted on September 24, 2021.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Ran Zheng was appointed as Class I Director at Caribou Biosciences, Inc..

Action: appointed
Role: Class I Director

Exact text from the filing

On September 24, 2021, the Board of Directors (the “Board”) of Caribou Biosciences, Inc., a Delaware corporation (the “Company”), increased the size of the Board from five to six directors and unanimously agreed to extend an offer to Ran Zheng to serve as a Class I director of the Company, which offer Ms. Zheng accepted on September 24, 2021.

View on SEC.gov

Caribou Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-21-001925

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.